Background: Fungal infections, caused by different Candida species, represent a great medical issue and their diagnostic and treatment creates enormous expenses and burden for the healthcare sytem. Epidemiology of invasive and non-invasive candidiasis has significantly changed over the last decades, as much in prevalence of individual Candida species, as in development of resistance to antifungal drugs. Although C. albicans was the leading cause of invasive candidiasis for many years, around 50 % of contemporary infections are caused by non-albicans species. Objectives: The aim of this study was to determine the distribution of the most significant Candida species, that were tested for antifungal susceptibility. The aim was also to determine the frequency of Candida strains resistant to tested drugs in the University Hospital of Split in 2018. Materials and methods: In this retrospective study, dana has been used form the archive of Department od Microbiology and Parasitology, University Hospital of Split. The information about all clinically significant Candida strains, that were tested for antifungal susceptibility in period of the study, was collected. Repetative or so-called “copy” strains were not included in the analysis. Quantitative data is described with median and mean value, while categorial variables are expressed with absolute numbers and percentages. The differnces between values of the data in the observed species were analysed using chi-square test. The level of statistical significance was set to p ≤0,05. Results: In the period of the study, 146 Candida species were tested for antifungal susceptibility, out of which 79 % belonged to non-albicans species, which is significantly higher than the number of tested C. albicans isolates (21 %). Most frequently tested species were C. glabrata (32 %), C. albicans (21 %) and C. parapsilosis (27 %). Resistance of non-albicans species to fluconazole (76 %) was significantly higher than the resistance of C. albicans (33 %). Results of this study show that 25,8 % of all tested C. albicans isolates and 16% of tested non-albicans isolates, are resistant to echinocandins. Conclusion: Higher proportion of tested non-albicans Candida isolates than C. albicans isolates, as well as recorded resistance to frequently used antifungal drugs, emphasizes the need of continuous antimicrobal surveillance and susceptibility testing of different Candida species to antifungal drugs. Analysing and monitoring trends of prevalence of individual Candida species, and their resistance to antifungal drugs, can help in establishing algorithms for empirical and final antifungal therapy.